Olinvacimab

Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a Kd value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer.

Olinvacimab (0-1000 nM) inhibits binding of VEGF to its receptor KDR with a Kd value of 0.23 nM[1].Olinvacimab inhibits VEGF-165, VEGF-C and VEGF-D binding to VEGFR-2 with IC50 values of 8.7, 6.3 and 7.0 nM, respectively[1].Olinvacimab (0.5-30 μg/mL; 30 min) inhibits the phosphorylation of VEGFR-2/KDR and ERK[1].Olinvacimab (1, 15 and 20 mg/mL; 30 min) inhibits VEGF-induced proliferation of HUVEC[1].Olinvacimab (20 mg/mL; 30 min) inhibits VEGF-stimulated HUVEC migration[1].Olinvacimab (5, 10 and 20 μg; 20 h) dose-dependently inhibits tube formation and disorders tubular structures[1].Olinvacimab (1 and 20 μg; 6 d) inhibits hVEGF165-induced rat aortic ring vessel sprouting[1].

Olinvacimab (100 ng; s.c., once) inhibits angiogenesis in vivo[1].

References:
[1]. Lee WS, et al. TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis. MAbs. 2015;7(5):957-68.